-
公开(公告)号：US20170174710A1
公开(公告)日：2017-06-22
申请号：US15368454
申请日：2016-12-02
Applicant: BIOGEN MA INC.
Inventor： Kevin M. Guckian , Gnanasambandam Kumaravel , Bin Ma , Sha Mi , Hairuo Peng , Zhaohui Shao , Lihong Sun , Arthur G. Taveras , Zhili Xin , Lei Zhang
IPC: C07F7/08 , C07C229/50 , A61K31/196 , C07D215/12 , A61K31/47 , C07D401/04 , A61K31/4545 , A61K31/506 , C07D295/096 , A61K31/495 , C07D213/74 , A61K31/496 , A61K31/551 , C07D239/42 , C07D241/20 , A61K31/497 , C07D211/14 , A61K31/451 , C07D205/04 , A61K31/397 , C07D401/06 , A61K31/4709 , C07D491/107 , C07D209/52 , A61K31/403 , C07D451/02 , A61K31/439 , A61K31/695 , C07C233/60 , C07D215/38 , C07D451/14 , A61K45/06
CPC classification number: C07F7/081 , A61K31/195 , A61K31/196 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/439 , A61K31/451 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K45/06 , C07C211/38 , C07C217/58 , C07C229/46 , C07C229/50 , C07C233/60 , C07C233/61 , C07C235/66 , C07C2102/10 , C07C2102/42 , C07C2102/44 , C07C2102/50 , C07C2103/62 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/42 , C07C2602/44 , C07C2602/46 , C07C2602/50 , C07C2603/62 , C07C2603/74 , C07D205/04 , C07D209/52 , C07D211/14 , C07D213/74 , C07D215/12 , C07D215/20 , C07D215/38 , C07D217/22 , C07D239/42 , C07D241/20 , C07D295/096 , C07D401/04 , C07D401/06 , C07D451/02 , C07D451/14 , C07D471/08 , C07D491/107 , C07F7/0805 , A61K2300/00
Abstract: Compounds of formula (I) can modulate the activity of one or more S1P receptors and/or the activity of autotaxin (ATX).
-
公开(公告)号：US09555050B2
公开(公告)日：2017-01-31
申请号：US14417353
申请日：2013-07-26
Applicant: BIOGEN MA INC.
Inventor： Kevin Guckian , Gnanasambandam Kumaravel , Bin Ma , Sha Mi , Zhaohui Shao , Lihong Sun , Arthur Taveras , Deping Wang , Zhili Xin , Lei Zhang
IPC: C07D215/20 , A61K31/662 , A61K45/06 , C07D401/04 , C07D401/06 , C07C229/48 , C07D265/30 , C07D211/34 , C07D211/62 , C07D213/79 , C07D223/06 , C07C233/47 , C07D205/04 , C07D207/08 , C07D207/16 , C07C229/46 , C07F9/38 , A61K31/196 , A61K31/397 , A61K31/435 , A61K31/445 , A61K31/454 , A61K31/47 , A61K31/5375 , A61K31/55 , C07D213/80
CPC classification number: A61K31/662 , A61K31/196 , A61K31/397 , A61K31/435 , A61K31/445 , A61K31/454 , A61K31/47 , A61K31/5375 , A61K31/55 , A61K45/06 , C07B2200/07 , C07C229/46 , C07C229/48 , C07C233/47 , C07C2601/02 , C07C2601/04 , C07C2601/14 , C07C2602/26 , C07D205/04 , C07D207/08 , C07D207/16 , C07D211/34 , C07D211/62 , C07D213/79 , C07D213/80 , C07D215/20 , C07D223/06 , C07D265/30 , C07D401/04 , C07D401/06 , C07F9/38 , C07F9/3808
Abstract: Compounds of formula (I) can modulate the activity of autotaxin (ATX).
Abstract translation: 式（I）化合物可调节自分泌素（ATX）的活性。
-
公开(公告)号：US09522889B2
公开(公告)日：2016-12-20
申请号：US14417300
申请日：2013-07-26
Applicant: BIOGEN MA INC.
Inventor： Kevin Guckian , Gnanasambandam Kumaravel , Bin Ma , Sha Mi , Hairuo Peng , Zhaohui Shao , Lihong Sun , Arthur Taveras , Deping Wang , Zhili Xin , Lei Zhang
IPC: A61K31/015 , A61K31/44 , A61K31/4375 , C07D295/096 , C07D223/06 , A61K45/06 , C07D217/22 , C07D471/08 , C07D211/34 , C07D211/62 , C07C255/59 , C07C229/46 , C07C229/48 , A61K31/136 , A61K31/196 , A61K31/439 , A61K31/445 , A61K31/46 , A61K31/5375 , A61K31/55 , C07C217/22 , C07D209/52 , C07D221/22
CPC classification number: C07D451/02 , A61K31/136 , A61K31/196 , A61K31/439 , A61K31/445 , A61K31/46 , A61K31/472 , A61K31/4725 , A61K31/5375 , A61K31/55 , A61K45/06 , C07B2200/07 , C07C217/22 , C07C229/46 , C07C229/48 , C07C255/59 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D209/52 , C07D211/34 , C07D211/62 , C07D217/22 , C07D221/22 , C07D223/06 , C07D295/096 , C07D401/06 , C07D471/08 , Y02A50/401
Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
Abstract translation: 公开了式（I）的双环芳基化合物，其可以调节自分泌素（ATX）酶的活性。 本发明还涉及作为ATX抑制剂的化合物，以及制备和使用这些化合物治疗由于损伤或疾病引起的脱髓鞘以及治疗增殖性疾病如癌症的方法。
-
公开(公告)号：US20160083468A1
公开(公告)日：2016-03-24
申请号：US14750368
申请日：2015-06-25
Applicant: Biogen MA Inc.
Inventor： Sha Mi , R. Blake Pepinsky , Christilyn Graff
IPC: C07K16/28 , A61K39/395 , A61K47/48
CPC classification number: C07K16/2803 , A61K39/3955 , A61K45/06 , A61K47/60 , A61K47/6849 , A61K47/6879 , A61K2039/505 , C07K16/18 , C07K16/28 , C07K2317/21 , C07K2317/35 , C07K2317/41 , C07K2317/51 , C07K2317/515 , C07K2317/54 , C07K2317/55 , C07K2317/56 , C07K2317/565 , C07K2317/71 , C07K2317/76 , C07K2317/92 , C07K2317/94 , C07K2319/01
Abstract: Endogenous LINGO-1 is a negative regulator for neuronal survival, axon regeneration, oligodendrocyte differentiation and myelination. Molecules that block endogenous LINGO-1 function, such anti-LINGO-1 antibodies can be used as therapeutics for the treatment of neuron and oligodendrocyte dysfunction. The present invention provides antibodies specific for LINGO-1, and methods of using such antibodies as antagonists of endogenous LINGO-1 function. The invention further provides specific hybridoma and phage library-derived monoclonal antibodies, nucleic acids encoding these antibodies, and vectors and host cells comprising these antibodies. The invention further provides methods of promoting oligodendrocyte survival and myelination in a vertebrate, comprising administering to a vertebrate in need of such treatment an effective amount of an anti-LINGO-1 antibody
-
公开(公告)号：US10894040B2
公开(公告)日：2021-01-19
申请号：US16542746
申请日：2019-08-16
Applicant: BIOGEN MA INC.
Inventor： Jermaine Thomas , Sha Mi , Edward Yin-Shiang Lin , Guo Zhu Zheng , Bin Ma , Richard D. Caldwell , Kevin Guckian , Gnanasambandam Kumaravel
IPC: A61K31/445 , C07D211/34 , C07D211/60 , C07D211/62 , C07D405/12 , C07D401/06 , C07D215/20 , A61K31/225 , A61K31/4545 , A61K31/4709 , A61K31/498 , A61K31/517 , A61K31/55 , A61K31/695 , A61K38/21 , A61K39/395 , C07K16/28
Abstract: The present invention provides compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and their use in modulating the activity of S1P) receptors. Also provided is a pharmaceutical composition comprising the compounds of formula (I) or (II) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient or carrier.
-
Patent Agency Ranking
公开(公告)号：US20200216533A1
公开(公告)日：2020-07-09
申请号：US16589322
申请日：2019-10-01
Applicant: Biogen MA Inc.
Inventor： Diego Cadavid , Sha Mi
IPC: C07K16/28 , A61K38/21 , A61K39/395 , A61K45/06
Abstract: Methods, compositions and kits are described herein useful for detecting and/or treating a CNS demyelinating disease.
-
公开(公告)号：US10017506B2
公开(公告)日：2018-07-10
申请号：US15296601
申请日：2016-10-18
Applicant: BIOGEN MA INC.
Inventor： Kevin M. Guckian , Gnanasambandam Kumaravel , Bin Ma , Sha Mi , Hairuo Peng , Zhaohui Shao , Lihong Sun , Arthur G. Taveras , Deping Wang , Zhili Xin , Lei Zhang
IPC: A61K31/015 , A61K31/4375 , A61K31/44 , C07D451/02 , C07D217/22 , A61K31/472 , A61K45/06 , A61K31/4725 , C07D401/06
CPC classification number: C07D451/02 , A61K31/136 , A61K31/196 , A61K31/439 , A61K31/445 , A61K31/46 , A61K31/472 , A61K31/4725 , A61K31/5375 , A61K31/55 , A61K45/06 , C07B2200/07 , C07C217/22 , C07C229/46 , C07C229/48 , C07C255/59 , C07C2601/04 , C07C2601/08 , C07C2601/14 , C07C2602/42 , C07D209/52 , C07D211/34 , C07D211/62 , C07D217/22 , C07D221/22 , C07D223/06 , C07D295/096 , C07D401/06 , C07D471/08 , Y02A50/401
Abstract: Disclosed are bicyclic aryl compounds of formula (I), that can modulate the activity of the autotaxin (ATX) enzyme. This invention further relates to compounds that are ATX inhibitors, and methods of making and using such compounds in the treatment of demyelination due to injury or disease, as well as for treating proliferative disorders such as cancer.
-
公开(公告)号：US20180148505A1
公开(公告)日：2018-05-31
申请号：US15541944
申请日：2016-01-08
Applicant: Biogen MA Inc.
Inventor： Diego Cadavid , Sha Mi
IPC: C07K16/28 , A61K39/395 , A61K45/06 , A61K38/21 , A61K39/00
CPC classification number: C07K16/2803 , A61K38/215 , A61K39/3955 , A61K45/06 , A61K2039/505 , A61K2039/54 , A61K2039/545 , C07K2317/21 , C07K2317/76
Abstract: Methods, compositions and kits comprising an anti-LINGO antibody molecule are described herein useful for detecting and/or treating a CNS demyelinating disease.
-
19.发明授权公开(公告)号：US09550798B2
公开(公告)日：2017-01-24
申请号：US14417293
申请日：2013-07-26
Applicant: BIOGEN MA INC.
Inventor： Kevin Guckian , Gnanasambandam Kumaravel , Bin Ma , Sha Mi , Hairuo Peng , Zhaohui Shao , Lihong Sun , Arthur Taveras , Zhili Xin , Lei Zhang
IPC: C07C229/48 , C07D223/06 , C07D221/22 , C07D209/52 , C07D211/62 , C07D295/096 , A61K31/5375 , A61K31/439 , A61K31/46 , A61K31/445 , A61K31/196 , A61K31/136 , C07F7/08 , A61K45/06 , A61K31/195 , A61K31/41 , A61K31/4709 , A61K31/4725 , A61K31/5513 , C07D215/38 , C07D217/22 , C07D401/04 , C07D471/08 , C07C217/58 , C07C229/46 , C07C233/61 , C07C235/66 , A61K31/397 , A61K31/4545 , A61K31/47 , A61K31/495 , A61K31/496 , A61K31/506 , A61K31/551 , A61K31/695 , C07C211/38 , C07D205/04 , C07D213/74 , C07D215/20 , C07D401/06
CPC classification number: C07F7/081 , A61K31/195 , A61K31/196 , A61K31/397 , A61K31/403 , A61K31/41 , A61K31/439 , A61K31/451 , A61K31/4545 , A61K31/47 , A61K31/4709 , A61K31/4725 , A61K31/495 , A61K31/496 , A61K31/497 , A61K31/506 , A61K31/551 , A61K31/5513 , A61K31/695 , A61K45/06 , C07C211/38 , C07C217/58 , C07C229/46 , C07C229/50 , C07C233/60 , C07C233/61 , C07C235/66 , C07C2102/10 , C07C2102/42 , C07C2102/44 , C07C2102/50 , C07C2103/62 , C07C2601/10 , C07C2601/14 , C07C2602/08 , C07C2602/10 , C07C2602/42 , C07C2602/44 , C07C2602/46 , C07C2602/50 , C07C2603/62 , C07C2603/74 , C07D205/04 , C07D209/52 , C07D211/14 , C07D213/74 , C07D215/12 , C07D215/20 , C07D215/38 , C07D217/22 , C07D239/42 , C07D241/20 , C07D295/096 , C07D401/04 , C07D401/06 , C07D451/02 , C07D451/14 , C07D471/08 , C07D491/107 , C07F7/0805 , A61K2300/00
Abstract: Compounds of formula (I) can modulate the activity of one or more SIP receptors and/or the activity of autotaxin (ATX).
Abstract translation: 式（I）化合物可以调节一种或多种SIP受体的活性和/或自分泌素（ATX）的活性。
-
公开(公告)号：US20160002329A1
公开(公告)日：2016-01-07
申请号：US14734144
申请日：2015-06-09
Applicant: Biogen MA Inc.
Inventor： Sha Mi , R. Blake Pepinsky , John McCoy
CPC classification number: C07K16/28 , A01K67/0275 , A01K67/0276 , A01K2217/075 , A01K2227/105 , A01K2267/0393 , A61K2039/505 , C07K14/4702 , C07K16/18 , C07K16/2863 , C07K16/32 , C07K16/40 , C07K2317/74 , C07K2317/75 , C07K2317/76 , C07K2317/92 , C07K2319/30 , C12N15/8509
Abstract: The invention provides methods of treating diseases, disorders or injuries involving demyelination and dysmyelination, including multiple sclerosis, by the administration of an Sp35 antagonist. Additional methods include methods for inhibiting the binding of the Sp35 polypeptide with the ErbB2 polypeptide and a method for increasing ErbB2 phosphorylation by contacting oligodendrocytes with an effective amount of a composition comprising an Sp35 antagonist of the invention. Further embodiments of the invention include methods of inhibiting the binding of the Sp35 polypeptide with the ErbB2, increasing ErbB2 phosphorylation and promoting oligodendrocyte differentiation comprising contacting oligodendrocyte or oligodendrocyte progenitor cells with an ErbB2 binding agent.
Abstract translation: 本发明提供了通过施用Sp35拮抗剂治疗涉及脱髓鞘和髓鞘脱离（包括多发性硬化）的疾病，病症或损伤的方法。 另外的方法包括用于抑制Sp35多肽与ErbB2多肽的结合的方法以及通过使少突胶质细胞与有效量的包含本发明的Sp35拮抗剂的组合物接触来增加ErbB2磷酸化的方法。 本发明的其它实施方案包括抑制Sp35多肽与ErbB2结合的方法，增加ErbB2磷酸化和促进少突胶质细胞分化，包括使少突胶质细胞或少突胶质细胞祖细胞与ErbB2结合剂接触。
-
-
-
-
-
-
-
-
-
Search Results
36
records
(took 0.031 seconds)
